The Filing Desk

BridgeBio Pharma vs Mirum Pharmaceuticals

BridgeBio Pharma BBIO · Mirum Pharmaceuticals MIRM · Pharmaceuticals

Mirum Pharmaceuticals reported revenue of $521 million in fiscal 2025, about the same as BridgeBio Pharma's $502 million in fiscal 2025. BridgeBio Pharma's revenue grew 126.3% in its latest year, and Mirum Pharmaceuticals' grew 54.7%. BridgeBio Pharma had an operating margin of -104.2%, against -4.2% at Mirum Pharmaceuticals. Free cash flow was −$447 million at BridgeBio Pharma and $55 million at Mirum Pharmaceuticals.

Side by side

BridgeBio PharmaMirum Pharmaceuticals
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$502M$521M
Revenue growth126.3%54.7%
Revenue growth a year, last 5 years127.7%—
Gross margin95.8%—
Operating margin−104.2%−4.2%
Net margin−146.0%−4.5%
Free cash flow−$447M$55M
Free cash flow margin−89.0%10.5%
Return on capital—−7.1%
Net debt to EBITDA—−34.9x
Dividends and buybacks$48M$0M
Change in diluted share count2.9%5.6%
Last close$78.18$95.51
P/E at the last close——
Insider trades, last 12 monthssold $86.2 millionbought $9.0 million, sold $43.1 million
Piotroski F-score3 of 95 of 8
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
BridgeBio PharmaMirum Pharmaceuticals
Operating margin
Percent of revenue
BridgeBio PharmaMirum Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
BridgeBio PharmaMirum Pharmaceuticals

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the BridgeBio Pharma and Mirum Pharmaceuticals pages.